ArticleMolecular biology reports2026
Immune protection mediated by Echinococcus granulosus EgM123 in the dextran sodium Sulfate-induced colitis model in mice.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeInflammatory bowel disease (IBD) is a chronic inflammatory disease characterized by damage to the epithelial barrier and intestinal inflammation; there is currently no standard treatment. Recent evidence suggests that worms and their by-products may have potential to treat IBD, owing to their immunomodulatory effects in humans. We investigated the effects of the recombinant Echinococcus granulosus antigen EgM123 on host immunity and inflammation.
methodsWe produced recombinant EgM123 to test its effects in the dextran sodium sulfate (DSS)-induced colitis mouse model. Mice were immunized with EgM123 three times via intraperitoneal injection and then challenged with 4% DSS in the drinking water for 1 week; they were observed daily for weight, mobility, and stool. After necropsy, fixed tissues/organs were sectioned and stained with hematoxylin and eosin to assess inflammation. Cytokine levels were detected by ELISA and reverse transcription polymerase chain reaction. Colitis severity was assessed by colon length, weight loss, and a semi-quantitative score of morphological changes.
resultsEgM123 had protective effects against colitis in mice. Histopathological analysis of the colon revealed a significant reduction in intestinal inflammation caused by DSS, which was associated with downregulation of the Th1/Th17 response in the colon. Administration of EgM123 before colitis induction limited the severity of intestinal inflammation and the disease index score, inhibited TNF-α secretion, and induced IL-10 expression.
conclusionsEgM123 may alleviate colitis by inhibiting the Th1 response and inducing Th2 immunity. Immunotherapy with EgM123 may represent a strategy to modulate the inflammatory processes involved in IBD.
Indexed as
Identifiers
41533207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.